Chronobiology of blood pressure: Emerging implications of melatonin

European Journal of Clinical Investigation

Volumn 42, Issue 11, 2012, Pages 1252-1254

  Simko, Fedor ^a,b,c  

^a Bratislava   (Slovakia)

^b INSTITUTE OF EXPERIMENTAL ENDOCRINOLOGY   (Slovakia)

^c Center of Excellence NOREG   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MELATONIN;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONOBIOLOGY; CHRONOTHERAPY; CIRCADIAN RHYTHM; ESSENTIAL HYPERTENSION; EVENING DOSAGE; HEART INFARCTION; HUMAN; HYPERTENSION; MORNING DOSAGE; NONHUMAN; NOTE; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RESISTANT HYPERTENSION; SIDE EFFECT; SUDDEN DEATH; TREATMENT PLANNING;

BLOOD PRESSURE; CIRCADIAN RHYTHM; DRUG CHRONOTHERAPY; HUMANS; MELATONIN;

EID: 84867744333     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2012.02705.x     Document Type: Note

References (16)

1. Nishiyama A, Imai Y, Ohkubo T, Tsuji I, Nagai K, Kikuchi N et al. Relation between nocturnal decline of blood pressure and mortality: the Ohasama study. Am J Hypertens 1997;10:1201-7.
2. Hermida RC, Ayala DE, Mojón A, Fernández JR. Decreasing sleep-time blood pressure determined by ambulatory monitoring reduces cardiovascular risk. J Am Coll Cardiol 2011;58:1165-73.
3. Hermida RC, Ayala DE, Mojón A, Fernández JR. Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Chronobiol Int 2010;27:1629-51.
4. Kario K. Aremelatoninand its receptor agonist specific antihypertensive modulators of resistant hypertension caused by disrupted circadian rhythm? J Am Soc Hypertens 2011;5:354-8.
5. Charmandari E, Chrousos GP, Lambrou GI, Pavlaki A, Koide H, Ng SS et al. Peripheral CLOCK regulates target-tissue glucocorticoid receptor transcriptional activity in a circadian fashion in man. PLoS One 2011;6:e25612. doi:10.1371/journal.pone.0025612.
6. Simko F, Pechanova O. Potential roles of melatonin and chronotherapy among the new trends in hypertension treatment. J Pineal Res 2009;47:127-33.
7. Reiter RJ, Tan DX, Manchester LC, Pilar Terron M, Flores LJ et al. Medical implications of melatonin: receptor-mediated and receptor-independent actions. Adv Med Sci 2007;52:11-28.
8. Reiter RJ, Tan DX, Fuentes-Broto L. Melatonin: a multitasking molecule. Prog Brain Res 2010;181:127-51.
9. Simko F, Paulis L. Melatonin as a potential antihypertensive treatment. J Pin Res 2007;42:319-22.
10. Simko F, Pechanova O, Pelouch V, Krajcirovicova K, Mullerova M, Bednarova K et al. Effect of melatonin, captopril, spironolactone and simvastatin on blood pressure and left ventricular remodeling in spontaneously hypertensive rats. J Hypertens 2009;27(Suppl 6):S5-10.
11. Grossman E, Laudon M, Zisapel N. Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials. Vasc Health Risk Manag 2011;7:577-84.
12. Jonas M, Garfinkel D, Zisapel N, Laudon M, Grossman E. Impaired nocturnal melatonin secretion in non-dipper hypertensive patients. Blood Press 2003;12:19-24.
13. Gooley JJ, Chamberlain K, Smith KA, Khalsa SB, Rajaratnam SM, Van Reen E et al. Exposure to room light before bedtime suppresses melatonin onset and shortens melatonin duration in humans. J Clin Endocrinol Metab 2011;96:E463-72.
14. Reiter RJ, Tan DX, Korkmaz A. The circadian melatonin rhythm and its modulation: possible impact on hypertension. J Hypertens 2009;27(Suppl 6):S17-20.
15. Hermida RC, Ayala DE, Fernández JR, Calvo C. Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension. Hypertension 2008;51:69-76.
16. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.